InMed Pharmaceuticals Inc
inmedpharma.comWhat Do They Do?
Develops proprietary small-molecule drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration and epidermolysis bullosa.
10-K for FY2026, filed Sep 9, 2026
Sources
How Do They Make Money?
FY2025
revenue
Revenue, FY2025
$4.9M
Sources
-
10-K for FY2025, filed Sep 23, 2025
$4.9M ↗
Do Revenues Turn Into Profits?
No. It lost $8.2M in FY2025.
Operating income, FY2025
−137% of revenue
▼ −17% (Loss)
vs FY2024 (−$8.2M, −178%)
Net income, FY2025
Sources
10-K for FY2026, filed Sep 9, 2026
−$8.2MView ↗
▲ +6% (Loss)
vs FY2024 (−$7.7M, −167%)
How Are They Changing?
Since the FY2026 annual report
-
Sep 16, 2026
Nasdaq notified InMed that its equity fell below the continued-listing requirement
The notice does not immediately affect trading; InMed expects the Mentari merger to close in the fourth quarter of 2026, subject to shareholder approval.
Sources
8-K, filed Sep 18, 2026
On September 16, 2026, InMed Pharmaceuticals Inc. (the "Company") received a letter from the Listing Qualifications Department of The…View ↗
Growing. Revenue grew 4.5x in 3 years, from $1.1M in FY2022 to $4.9M in FY2025, about 66% a year.
Loading...
Comments
